Target intelligence / Profile preview

14-3-3 protein (general family; e.g., "14-3-3 protein beta" for specific isoform) (14-3-3)

Target
14-3-3
Molecular classification
Regulatory protein, Molecular scaffold, Signal transduction adapter, Phosphoserine/phosphothreonine binding protein
01

Overview

14-3-3 proteins are a highly conserved family of regulatory molecules found in all eukaryotic cells. They function primarily as molecular scaffolds, binding to hundreds of phosphoserine/threonine-containing proteins across diverse signaling pathways. Seven distinct human isoforms exist, often forming homo- or heterodimers. They play crucial roles in signal transduction, cell cycle progression, cell death, and trafficking by altering the conformation, function, or localization of their binding partners. Dysregulation or altered expression of 14-3-3 proteins is implicated in diseases such as cancer and neurodegenerative disorders, and elevated cerebrospinal fluid levels are a diagnostic marker for rapid neurodegeneration. While no approved drugs specifically target these proteins, their protein–protein interaction surfaces are being explored for pharmacological intervention, though safety and specificity remain challenges.

Other names
14-3-3 proteinsTyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation proteinYWH family (e.g., YWHAB, YWHAE for specific isoforms)
02

Mechanism of action

Modulate protein–protein interactions by stabilizing or inhibiting binding between 14-3-3 and partners Affect localization and function of signaling proteins

03

Biological functions

Signal transductionCell cycle regulationApoptosisCell proliferationImmune responseTraffickingNeurodegenerationStress response
04

Disease associations

CancerNeurodegenerative disease (e.g., indicative in Creutzfeldt–Jakob disease)Cardiovascular diseaseOther chronic and acute diseases
05

Safety considerations

Targeting scaffolding proteins like 14-3-3 may disrupt multiple signaling pathways, raising the risk of off-target effects and toxicityEssential for survival of eukaryotic cells, making complete inhibition potentially detrimental
06

Interacting drugs

No approved drugs directly target 14-3-3 proteins; several research compounds and tool molecules exist, including protein-protein interaction modulators

2 more in the full profile.

07

Biomarkers

Cerebrospinal fluid 14-3-3 protein levels are used as biomarkers for rapid neurodegeneration (e.g., Creutzfeldt–Jakob disease)Potential tissue and serum signatures for certain cancers and neurodegenerative diseases

Beyond the preview

Go deeper on 14-3-3 protein (general family; e.g., "14-3-3 protein beta" for specific isoform) (14-3-3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 14-3-3 protein (general family; e.g., "14-3-3 protein beta" for specific isoform) (14-3-3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call